CARTISTEMの新興薬剤に関する洞察と市場予測：2032年

CARTISTEMは、変形性膝関節症患者（ICRSグレードIVの軟骨欠損を有する）の変性または反復性外傷による膝軟骨欠損の治療に使用される同種臍帯血由来間葉系幹細胞（UCB-MSC）です。ICRSグレードとは、軟骨欠損の重症度を評価するための診断基準です。グレードIVは最も重篤な段階であり、欠損部に軟骨が全く残っていない状態です。

メディポストはまた、2つの戦略で日本市場への参入を計画しています。最近承認された第III相臨床試験とは別に、軽度から重度の膝関節OA（K&Lグレード2-4）患者50人を対象に、HTO（High Tibial Osteotomy、腸脛骨骨切り術、腸脛靭帯骨切り術）の効果をCARTISTEMの有無で比較する第II相臨床試験が、2020年後半からの条件付き製品承認取得に向けて進行中です。

当レポートでは、主要6ヶ国、カナダ、および韓国におけるCARTISTEM市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 変形性関節症に対するCARTISTEMの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 CARTISTEM市場評価

• 変形性関節症に対するCARTISTEMの市場展望
• 主要6ヶ国、カナダ、および韓国の分析
  • 主要6ヶ国、カナダ、および韓国における変形性関節症に対するCARTISTEMの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国
  • カナダ
  • 韓国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: CARTISTEM, Clinical Trial Description, 2023
• Table 2: CARTISTEM, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: CARTISTEM Market Size in the 6MM, Canada and Korea, in USD million (2019-2032)
• Table 6: CARTISTEM Market Size in the US, in USD million (2019-2032)
• Table 7: CARTISTEM Market Size in Germany, in USD million (2019-2032)
• Table 8: CARTISTEM Market Size in France, in USD million (2019-2032)
• Table 9: CARTISTEM Market Size in Italy, in USD million (2019-2032)
• Table 10: CARTISTEM Market Size in Spain, in USD million (2019-2032)
• Table 11: CARTISTEM Market Size in the UK, in USD million (2019-2032)
• Table 12: CARTISTEM Market Size in Canada, in USD million (2019-2032)
• Table 13: CARTISTEM Market Size in Korea, in USD million (2019-2032)

List of Figures

• Figure 1: CARTISTEM Market Size in the 6MM, Canada and Korea, USD million (2019-2032)
• Figure 2: CARTISTEM Market Size in the United States, USD million (2019-2032)
• Figure 3: CARTISTEM Market Size in Germany, USD million (2019-2032)
• Figure 4: CARTISTEM Market Size in France, USD million (2019-2032)
• Figure 5: CARTISTEM Market Size in Italy, USD million (2019-2032)
• Figure 6: CARTISTEM Market Size in Spain, USD million (2019-2032)
• Figure 7: CARTISTEM Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: CARTISTEM Market Size in Canada, USD million (2019-2032)
• Figure 9: CARTISTEM Market Size in Korea, USD million (2019-2032)

“"CARTISTEM Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CARTISTEM for osteoarthritis in the six major markets. A detailed picture of the CARTISTEM for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the CARTISTEM for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CARTISTEM market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary:

CARTISTEM is an allogeneic umbilical cord blood-derived mesenchymal stem cells (UCB-MSC) used to treat knee cartilage defects in patients with OA (with ICRS grade IV cartilage defect) caused by degeneration or repetitive trauma. ICRS grade is a diagnostic criterion used for grading the severity of cartilage defects. Grade IV is the most severe stage, with no visible cartilage remaining on the defect area.

Medipost is also planning to enter the Japanese market with a two-track strategy. Separately from the recently approved Phase III clinical trial and a Phase II clinical trial to compare the effects of HTO (High Tibial Osteotomy, a procedure to treat bowlegs [genu varum]) with/without CARTISTEM in 50 patients with mild to severe knee OA (K&L Grade 2-4) is ongoing to obtain conditional product approval since the second half of 2020.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the CARTISTEM description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on CARTISTEM regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CARTISTEM research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around CARTISTEM.
• The report contains forecasted sales of CARTISTEM for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for CARTISTEM in osteoarthritis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CARTISTEM Analytical Perspective by DelveInsight

• In-depth CARTISTEM Market Assessment

This report provides a detailed market assessment of CARTISTEM for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

• CARTISTEM Clinical Assessment

The report provides the clinical trials information of CARTISTEM for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CARTISTEM dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to CARTISTEM and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CARTISTEM in osteoarthritis.
• Our in-depth analysis of the forecasted sales data of CARTISTEM from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CARTISTEM in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of CARTISTEM?
• What is the clinical trial status of the study related to CARTISTEM in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CARTISTEM development?
• What are the key designations that have been granted to CARTISTEM for osteoarthritis?
• What is the forecasted market scenario of CARTISTEM for osteoarthritis?
• What are the forecasted sales of CARTISTEM in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to CARTISTEM for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

Table of Contents

1. Report Introduction

2. CARTISTEM Overview in Osteoarthritis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. CARTISTEM Market Assessment

• 5.1. Market Outlook of CARTISTEM in Osteoarthritis
• 5.2. 6MM, Canada and Korea Analysis
  • 5.2.1. Market Size of CARTISTEM in the 6MM, Canada and Korea for Osteoarthritis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of CARTISTEM in the United States for Osteoarthritis
  • 5.3.2. Market Size of CARTISTEM in Germany for Osteoarthritis
  • 5.3.3. Market Size of CARTISTEM in France for Osteoarthritis
  • 5.3.4. Market Size of CARTISTEM in Italy for Osteoarthritis
  • 5.3.5. Market Size of CARTISTEM in Spain for Osteoarthritis
  • 5.3.6. Market Size of CARTISTEM in the United Kingdom for Osteoarthritis
  • 5.3.7. Market Size of CARTISTEM in Canada for Osteoarthritis
  • 5.3.8. Market Size of CARTISTEM in Korea for Osteoarthritis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options